Skip to main content
. 2014 Dec 22;125(8):1236–1243. doi: 10.1182/blood-2014-08-595801

Figure 2.

Figure 2

OS following treatment with brentuximab vedotin. OS was analyzed using Kaplan-Meier methodology and is shown overall (A) and by best response (B). All censored patients are indicated by dots on the Kaplan-Meier curve. Patients still on study and in remission without the start of new therapy are indicated by open dots on the Kaplan-Meier curve in panel A.